05 05 2016

UBS Wealth Management on $471 Million Oncology Impact Fund

King & Wood Mallesons has advised UBS Wealth Management, the world’s largest global wealth manager, on the final closing of its $471 million UBS Oncology Impact Fund, an impact investing initiative aimed at developing cancer treatments.


Investments will be made in early stage oncology to accelerate the development of new cures. Cancer care is particularly appropriate for this kind of investment because of a supportive regulatory environment.

The market for cancer drugs is expected to grow faster than for any other disease, due to populations ageing in developed countries and an expanding middle class in emerging markets with better access to care. Oncology is the largest and fastest growing therapeutic area in terms of drug development activity, representing approximately a quarter of total research spend. Impact investing aims to generate a defined positive social impact as well as a competitive return. It is an attractive area for investors who wish to align their portfolios with their values. It is potentially a highly significant source of capital for oncology, given cancer's wide-ranging social implications.

In addition to investing in early-stage cancer treatments, the Oncology Impact Fund will support academic research and better access to cancer care in the developing world. A portion of any performance fees generated and half of a royalty attached with best efforts to all successful drugs sales will be managed by UBS Optimus Foundation and ultimately fund expanded access to cancer care for children and their families in the developing world. The other half of the royalty amount will be spent on academic grants to promising oncology-related research. The Fund has already struck the first royalty agreement of this type, bringing this innovative practice from theory to reality. UBS Wealth Management is a leader in sustainable investment. The collaboration with MPM on the Oncology Impact Fund follows other programs including UBS Optimus Foundation’s Development Impact Bond focused on education in Rajasthan, India, support for investment vehicles that invest through funds into small and medium enterprises (SMEs) in developing countries and inclusive finance initiatives across Asia and Latin America. It also supports the aims of the UBS & Society program, which seeks to create long-term, sustainable and measurable benefits for clients and communities. The full King & Wood Mallesons team was led by International Funds partner Ajay Pathak and associate Josie Liao with support from funds associate Guillemette Chamayou; Tax partner Stephen Pevsner and associate Charlotte Haywood; Regulatory Counsel Karen Butler and partner George Pinkham (New York Office). Involved fees earner: Ajay Pathak - King & Wood Mallesons; Josie Liao - King & Wood Mallesons; Stephen Pevsner - King & Wood Mallesons; Charlotte Haywood - King & Wood Mallesons; Karen Butler - King & Wood Mallesons; George Pinkham - King & Wood Mallesons;

LATEST ISSUE
Powered by Share Trading

POPULAR ARTICLES
LE FONTI AWARDS 2017 CELEBRATE EXCELLENCES IN LONDON.

23/10/2017

On October 20th, 2017, the world’s leading corporate stars reunited for a speci

Le Fonti IAIR Awards Take Hong Kong By Storm

21/03/2017

Hong Kong has become a city of bright expansion, culture, and futuristic innovation. Fr

Will Brexit break London's place as FinTech Capital?

17/11/2016

Fintech, it’s described as the disruption in financial services pushed by consume

Le Fonti IAIR Awards 2016 celebrates excellences in London.

17/10/2016

On October 14th, 2016, the world’s leading corporate stars aligned for a momentou

IAIR AWARDS 2016 IN NEW YORK: EMONEY ADVISOR, C.A.S.H., CREDIT SUISSE AND CHEETAH MOBILE AMONG THE WINNERS

15/04/2016

More than 19 Excellences in the global economy at the VI Annual Edition of IAIR AWARDS&